Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ulta Beauty Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while Ulta Beauty Inc trades at $477.93 (market cap $20.17B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ALNY | ULTA | |
|---|---|---|
Market Cap | $39.89B | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $706.82 |
52-Week Low | $278.09 | $450.75 |
Enterprise Value | $38.15B | $22.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ULTA Beauty trades at $469.20, up 1.95% on the day, with a bearish technical signal but strong fundamentals including a 9.36% net income margin and 47.45% ROE. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89. The stock is near its pivot point of $457, with resistance at $470. Positive news highlights international expansion and a robust loyalty program driving 95% of sales.
The outlook is mixed: analyst consensus is bullish with a $623.73 price target, but technicals and recent net cash flow negativity pose risks. Investment opportunity lies in market share gains and AI-driven personalization, while headwinds include competitive pressures and margin compression from 11.42% in 2022 to 9.35% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
